CareDx Inc
NASDAQ:CDNA

  • LAST PRICE
    24.1100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    23.5000/ 2
  • Ask / Lots
    24.1000/ 1
  • Open / Previous Close
    --- / 24.1100
  • Day Range
    ---
  • 52 Week Range
    7.4200
    34.8400
  • Volume
    34

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
CDNA
CareDx Inc
1.2B
-8.9x
---
MRVI
Maravai LifeSciences Holdings Inc
1.3B
-3.2x
---
MDXG
MiMedx Group Inc
1.4B
18.3x
---
BCRX
BioCryst Pharmaceuticals Inc
1.6B
-12.0x
---
AUPH
Aurinia Pharmaceuticals Inc
1.3B
-55.1x
---
DVAX
Dynavax Technologies Corp
1.6B
102.3x
---
As of 2024-11-26

Company Information

CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.

Contact Information

Headquarters
8000 Marina Blvd, 4Th FloorBRISBANE, CA, United States 94005
Phone
415-287-2300
Fax
302-636-5454

Executives

Independent Chairman of the Board
Michael Goldberg
President, Chief Executive Officer, Director
John Hanna
Chief Financial Officer
Abhishek Jain
Chief Operating Officer
Keith Kennedy
General Counsel, Secretary
Jeffrey Novack

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.2B
Revenue (TTM)
$312.8M
Shares Outstanding
53.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.84
EPS
$-2.70
Book Value
$5.07
P/E Ratio
-8.9x
Price/Sales (TTM)
4.0
Price/Cash Flow (TTM)
---
Operating Margin
-50.05%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.